Otsuka Pharmaceutical, in strategic collaboration with Ionis Pharmaceuticals, has achieved a major regulatory milestone in the European market with its hereditary angioedema (HAE) prevention therapy, donidalorsen. On November 17, 2025, Otsuka announced that the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency’s scientific advisory panel, has issued a positive opinion, recommending donor approval for donidalorsen. This endorsement signals strong regulatory momentum for this innovative antisense oligonucleotide therapy aimed at managing and preventing hereditary angioedema attacks, a rare and potentially life-threatening condition marked by recurrent episodes of severe swelling.

The recommendation grants Otsuka and Ionis a pivotal advance in the competitive landscape of rare disease therapies within Europe, potentially securing one of the few CHMP approvals for HAE medications in recent years. The positive opinion is based on a comprehensive review of efficacy and safety data from multiple Phase III clinical trials conducted across Europe and additional global sites, involving hundreds of patients suffering from HAE. This review process evaluates donidalorsen’s therapeutic profile, its ability to significantly reduce the frequency and severity of HAE attacks compared to placebo and standard-of-care treatments, as well as its overall impact on patients’ quality of life and health resource utilization.

Donidalorsen leverages Ionis’ antisense technology to inhibit production of plasma kallikrein, a key enzymatic driver in HAE pathophysiology. The therapy is administered via subcutaneous injection and is engineered for once-monthly dosing, enhancing patient adherence and convenience compared to older intravenous or more frequent regimens. The CHMP’s assessment highlighted the robust reduction in attack rates demonstrated in pivotal studies and an acceptable safety profile, with the majority of adverse events classified as mild or moderate and manageable. No new safety signals were identified during the review period, supporting the therapy’s suitability for regulatory approval. If formally approved by the European Commission in the weeks following the CHMP positive opinion, donidalorsen could launch as an important addition to the European biopharmaceutical armamentarium for rare disease management.

For pharmaceutical executives, strategy leaders, and R&D heads, Otsuka’s achievement underlines several strategic trends in the European pharmaceutical landscape. Firstly, the endorsement demonstrates regulatory openness to advanced genetic and molecular technologies, paving the way for next-generation antisense and RNA-based therapies. Secondly, it highlights increasing investment and partnership activity in rare and orphan indications—a domain with substantial unmet medical need and pricing flexibility. Thirdly, the approval process reflects growing regulatory coordination and expedited pathways for critical therapies addressing life-threatening rare diseases. Otsuka and Ionis are positioned to leverage this upcoming approval to drive market expansion, distribution partnerships, and potential new indications for donidalorsen.

Operational teams and supply chain managers should anticipate market demand surges following European launch, necessitating calibrated manufacturing and logistics scaling for subcutaneous injectables. Clinical outsourcing teams and CRO/CMO providers may be engaged for post-marketing surveillance studies required by the EMA. Regulatory and compliance units should monitor for evolving guidance on genetic therapies and rare disease treatment protocols. The donidalorsen milestone represents not only a win for Otsuka/Ionis but also an indicator of Europe’s regulatory and commercial environment favoring innovation, partnership, and fast-track access for transformative therapies in the biopharmaceutical sector.